Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02092363 | Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer | PHASE1 | COMPLETED | 37 | — | — | Jan 1, 2014 | Dec 1, 2017 | Aug 12, 2020 | 4 | United States |
The maximum tolerated dose (MTD) will be determined in patients treated with OMP-54F28/paclitaxel/carboplatin (from Day 0 - 21)
| Arm | Type | Description |
|---|---|---|
| Drug: OMP-54F28, Paclitaxel and Carboplatin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| OMP-54F28, Paclitaxel and Carboplatin | DRUG | - |
Inclusion Criteria: * Signed Informed Consent Form * Age ≥18 years * Histologically documented ovarian, primary peritoneal or fallopian tube cancer * Recurrent platinum-sensitive disease, defined as disease progression ≥6 months after completing a minimum of 4 cycles of a platinum-containing regime...